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Abstract
Telomeres are nucleoprotein structures located at the ends of linear chromosomes. In 
most human adult normal somatic cells, telomeres shorten after each cellular division. 
This shortening ultimately leads to senescence and/or apoptosis. By contrast, in most 
cancer cells, telomerase activation compensates this loss and confers to these cells 
their infinite cell proliferation potential. Neuroblastoma (NBL) is a malignant tumor 
of the peripheral sympathetic nervous system and the most frequent extracranial solid 
tumor of childhood. NBLs are remarkably heterogeneous both at the levels of biol-
ogy, genetic and clinical courses. Indeed, some of NBLs can regress spontaneously or 
after a mild treatment, while others are in the high-risk category with poor progno-
sis. The molecular bases underlying this heterogeneity are poorly understood. MYCN 
(V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma-derived Homolog) 
amplification, recognized as strongly associated with unfavorable patient outcome, is 
found in only 40% of the high-risk disease, indicating the involvement of other mech-
anisms. Recent observations suggest that telomerase expression and telomere dys-
functions may be one critical step in NBL development. This review provides recent 
insights on telomeres/telomerase regulation in NBL. Because of their involvement in 
the tumor cell biology, telomere and telomerase are currently at the core of new drug 
development.
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1. Introduction
Cancer development is a multistep process requiring genetic and epigenetic events leading 
to the deregulation of the expression of key genes. Among these genes, telomerase, by its 
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action on telomere maintenance, plays a major contribution in carcinogenesis and drug resis-
tance. This enzyme is activated in almost 90% of cancers, including neuroblastoma (NBL).
Neuroblastoma is a malignant tumor of the peripheral sympathetic nervous system and the 
most common extracranial solid tumor in childhood [1, 2]. NBL is remarkably heterogeneous 
and displays a wide spectrum of differentiation stages from benign ganglioneuroma and well-
differentiated tumors to undifferentiated malignant NBL. NBL is also a heterogeneous disease 
in terms of outcome and response to treatments: from spontaneous regression to resistance 
to all known treatments. In about 60% of the cases, NBL is diagnosed as a disseminated high-
risk disease (stage 4), and most are diagnosed after 18 months of age. Genomic amplification 
of MYCN (V-Myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog) 
has been strongly associated with unfavorable patient outcome in approximately 20% of pri-
mary neuroblastoma tumors and approximately 40% of high-risk NBL. This alteration has 
thus been established as a robust marker for the definition of high-risk NBL. However, that 
MYCN amplification occurs only in 40% of high-risk NBL indicates that other genetic and/
or epigenetic alterations play an important role in this disease. Array comparative genomic 
hybridizations have been widely employed to discover genome abnormalities and evaluate 
patient’s risk. NBL displays several numerical and structural copy number variations such as 
the loss of 1p, 3p, 9p, 11q, and 14q, and the gain of 1q, 2p, and 17q, which identify high-risk 
subsets of NBL [3, 4]. That aggressive stage 4 neuroblastoma expressed high levels of telom-
erase activity, whereas favorable tumors had no or little telomerase expression and activity [5, 
6], suggest an important role of this enzyme in the biology of neuroblastoma and its response 
to chemotherapy. NBL has a very low mutation frequency. The most two mutated genes are 
ALK (anaplastic lymphoma kinase) coding a tyrosine kinase, altered in about 7–8% of all 
primary tumors and 50% of familial NBL cases [7, 8], and ATRX (alpha thalassemia/mental 
retardation syndrome, X-linked) in about 10% of NBL and generally found in older patients.
Recently, the next-generation sequencing has shown that high-risk NBLs are characterized by 
defects that in common lead to the activation of telomere maintenance pathways supporting 
the idea that targeting these pathways will benefit to the patients [9, 10].
Many excellent recent reviews [11, 12] already exist on telomeres and telomerase in many 
aspects (structure and functions, regulation, and epigenetic control). This paper will there-
fore briefly review the recent knowledge on this topic, then, it will focus on the mechanisms 
of telomerase reactivation and telomere length maintenance in NBL, and discuss how these 
regulatory mechanisms can be targeted or “manipulated” for therapeutic purposes to modify 
cell fate and anticancer drug response in NBL.
2. Telomeres and telomerase
2.1. Telomeres
Every normal human somatic cell has a molecular clock for dividing, a process discovered by 
Leonard Hayflick, half a century ago, who observed that diploid cells in culture can divide 
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only a limited number of times before stopping in a state known as the cellular senescence or 
the “Hayflick limit” [13]. In eukaryotic organisms, conventional DNA polymerases alone can-
not fully replicate the ends of linear chromosomes, called telomeres. Therefore, telomere ends are 
progressively shortened after each cellular division [14, 15]. This leads to genomic instability 
and senescence or apoptosis.
Telomeres are specialized nucleoprotein structures made of 10–15 kb of short non-protein-coding 
repetitive 5′-TTAGGG-3′ DNA sequences. Telomeric DNA is mainly double-stranded, ter-
minating in a single-stranded 3′ G-rich overhang of 150–200 nucleotides (nt) [16, 17]. These 
double-stranded repeats have one guanosine-rich strand (G-strand) copied by the lagging-
strand replication, and one cytosine-rich strand (C-strand) synthesized by leading-strand 
replication. The telomeric DNAs are bound by shelterin protein complexes consisting of telo-
meric repeat factors 1 and 2 (TRF1 and TRF2), repressor/activator protein 1 (RAP1), TRF1- 
and TRF2-interacting nuclear protein 2 (TIN2), tripeptidyl-peptidase 1 (TPP1), and protection 
of telomeres 1 (POT1) [18, 19]. TRF1 and TRF2 bind to the double-stranded telomere DNA 
repeats, whereas POT1 binds to the single-stranded G-rich overhang. The three remaining 
proteins of the shelterin complex act as adaptors to mediate the interactions between the com-
plex constituents: POT1 interacts with TPP1, a ternary complex of other proteins (TINT1/
PTOP/PIP1), which interacts in turn with TIN2 that plays a key role in stabilizing the shelterin 
complex via its interaction with TPP1, TRF1, and TRF2. TPP1 also plays a major role in con-
trolling the recruitment of the telomerase to the telomeres. RAP1 binds to TRF2 and acts as a 
mandatory element to the formation of the t-loop and the protection of the telomeres from the 
non-homologous end-joining (NHEJ) process. This process is dependent on the ataxia telan-
giectasia-mutated (ATM) kinase, the ataxia telangiectasia, and Rad3 (ATR) kinase, involved in 
the repair of the double-stranded and the single-stranded DNA breaks, respectively.
Due to the tandem organization of the G-rich telomeric DNA, the telomeres can form spe-
cialized four-stranded helical structures that involve Hoogsten-type base pairing between 
four guanines, named G-quadruplex (or G4) [20]. Alternatively, the G-strand overhang is also 
involved in the formation of the t-loop in which it invades the double-stranded region [21]. 
It has been hypothesized that those structures, which are not mutually exclusive, are able, by 
sequestering the 3′ end, to prevent the extension of the telomeres by telomerase.
Besides their role of capping chromosomes and protecting them from being recognized as 
DNA breaks [22], telomeres ensure proper chromosome segregation during mitosis [23] as 
well as transcriptional silencing of genes located close to them. Indeed, telomere shorten-
ing can alter gene expression by a process named telomere position effect (TPE) [24]. This 
process leads to the reversible silencing of genes near the telomere and thus is dependent 
on telomere length. In yeast, TPE can repress genes located up to 20 kb from the end [25, 26]. 
Recently, using a Hi-C (chromosome capture followed by high-throughput-sequencing) 
technique, three genes located at three different subtelomeric ends (1p, 6p, and 12p) were 
reported to have their expression altered with telomere length: ISG15 (interferon-stimulated 
gene 15kD), DSP (Desmoplakin), and C1S (complement component 1s subcomplement). This 
phenomenon occurs through chromosomal looping between the loci of these genes and their 
respective telomere ends [27, 28]. Therefore, many loci may be regulated by telomere length. 
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This observation provides a new potential mechanism by which telomere shortening could 
contribute to the aging process and cancer development.
Two mechanisms of telomere maintenance have been identified in humans: the telomerase-
mediated maintenance observed in 90% of cancers and, in the remaining 10%, the alternative 
lengthening of telomeres (ALT), which depends on homologous recombination [29, 30].
2.2. Telomerase: a ribonucleoprotein complex with multiple functions
Elizabeth Blackburn and her graduate student Carol Greider (2009 Nobel Prize in Physiology 
or Medicine) who worked on the ciliated protozoan Tetrahymena thermophila identified the 
enzyme responsible for the telomeric repeat synthesis [31]. This ribonucleoprotein (RNP) 
enzyme maintains telomere length by adding repetitive sequences to chromosome ends, 
slowing down telomere attrition [32].
Telomerase is an RNA-dependent DNA polymerase that plays a key role in carcinogenesis. 
By synthesizing telomeric DNA at the termini of chromosomes and stabilizing telomere 
lengths, it overcomes the senescence barrier due to the progressive telomere shortening asso-
ciated with cell divisions [33]. Normal human somatic cells have very low or undetectable 
telomerase activity. By contrast, this activity has been detected in a wide range of human 
cancers (85–90%), in stem cells and adult germline tissues [34, 35]. By its action on telomeres, 
this enzyme confers to cancer cells their infinite cell proliferation potential and controls cell 
survival [36–38]. Telomerase is believed to be a significant target in cancer therapy since its 
upregulation appears to be a feature of malignant cells.
The human telomerase is a ribonucleoprotein enzyme (127 kDa) composed of at least two 
components, a catalytic subunit, telomerase reverse transcriptase (hTERT), and a template 
RNA component (hTR) (Figure 1).
hTR is a non-polyadenylated 451-nt long non-coding RNA containing eight conserved 
regions (CR1–CR8) that acts mainly as a template for the synthesis of the telomeric DNA. hTR 
binds hTERT via a template-pseudoknot domain (CR1/CR2) and a stem-loop domain (CR4/
CR5) located in the middle of this RNA structure, which interacts with the DNA-binding 
domain of hTERT (Figure 1). hTERT protein functions as a dimer in the telomerase complex. 
Additional proteins are also required for a functional telomerase complex in vivo: small nucle-
olar RNPs, NHP2 (non-histone protein 2), NOP10 (nucleolar protein 10), GAR1, shelterin, and 
the ATPases Pontin and Reptin [39, 40]. The shelterin complex aids at the stabilization of the 
3′ end at the telomeres. The appropriate stabilization of hTR and its proper interaction with 
hTERT involves the recruitment of dyskerin (DKC1), an RNA-binding protein, facilitated by 
the ATPases Reptin and Pontin [41]. The assembly of telomerase occurs in the nucleus in the 
Cajal bodies, and its localization at telomeres requires TCAB1 (Telomerase CAjal Body pro-
tein 1) and TPP1 proteins [42, 43].
Loss-of-function mutations of either hTERT or hTR are associated with pathologies such as 
aplastic anemia, pulmonary fibrosis, and dyskeratosis congenital, diseases characterized by 
stem cell depletion, deficiency in tissue regeneration, and tissue atrophy [44].
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Besides its canonical role, accumulated evidence indicates that telomerase elicits other func-
tions in several essential cell-signaling pathways, including apoptosis, differentiation, DNA 
damage responses, and regulation of gene expression [45–50]. Even though these functions 
appear independent of telomerase activity, it is not excluded that some transient effect at 
telomeres can affect chromatin structure and gene expression. One example of these non-
canonical functions of hTERT is the demonstration that hTERT binds NF-κB p65 subunit 
and regulates some of its target genes such as IL (Interleukin)-6, IL-8, TNF (tumor necrosis 
factor) α, and matrix metallo proteinases (MMPs) [51, 52]. In turn, NF-κB (nuclear factor κ- 
light-chain-enhancer of activated B cells) can activate the expression of hTERT by binding to its 
promoter indicating a feed-forward loop between telomerase and NF-κB [53]. hTERT protein 
can also function as a transcriptional modulator of the Wnt (wingless-related integration site)/β-
catenin-signaling pathway [54]. Indeed, hTERT and β-catenin co-associate at the Wnt/β-catenin 
target gene promoters by forming a complex with the ATPase subunit of SWI/SNF (switch/
sucrose non-fermentable) chromatin-remodeling complex, BRG1 (Brahma-related gene 1). 
Interestingly both wild-type and catalytically inactive hTERT led to the reactivation of Wnt/β-
catenin target genes suggesting that this function is independent of its conventional func-
tion at telomeres. In turn, the Wnt/β-catenin pathway regulates the expression of hTERT in 
embryonic stem cells and in cancer cells through the recruitment of β-catenin to the promoter 
of hTERT indicating, in this case also, a positive feed-forward loop between telomerase and 
β-catenin [55]. Furthermore, functioning as an RNA-dependent RNA polymerase, hTERT 
has been implicated in the production of small-interfering (si) RNAs in a Dicer-dependent 
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Figure 1. The human telomere and telomerase: the human telomerase is composed at least of telomerase reverse 
transcriptase (hTERT), telomerase RNA component (hTR), and accessory proteins that are members of the H/ACA 
small nucleolar ribonucleoprotein family: dyskerin; NHP2 (non-histone protein 2); NOP10 (nucleolar protein 10); GAR1 
ribonucleoprotein.
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manner and thereby is involved in posttranscriptional gene silencing [56]. This activity of 
hTERT occurs through the interaction of hTERT protein with BRG1 and nucleostemin [57, 58]. 
For example, hTERT, through this activity, mediates the production of endogenous siRNAs 
using the RNA component of the mitochondrial RNA-processing endonuclease (RMRP) as a 
template.
Recently, it has been shown that BRG1 plays an essential role in maintaining the proliferation 
and viability of NBL cells. Interestingly, BRG1 is consistently upregulated in several NBL cell 
lines and in advanced stages of NBLs. Furthermore, high BRG1 levels have been correlated 
with poor patient outcome [59]. Therefore, BRG1 inhibition could be a possible new line of 
treatment for high-risk NBL patients. In view of these observations, the relationship between 
BRG1 and hTERT in NBL should be investigated.
2.3. Human hTERT regulation
Given the key role of telomerase in malignant transformation and tumor progression, great 
efforts have been deployed to unravel the mechanisms underlying telomerase activation.
2.3.1. hTERT gene and its promoter
The hTERT gene is 42-kb (kilobases) long with 16 exons [60] located in humans on the short 
arm of chromosome 5 (5p15.33) [61], more than 2 Mb away from telomeres. The reverse tran-
scriptase domain is coded by exons 5–9. Differential splicing of hTERT mRNA has been dem-
onstrated during embryonal development in various tissues. So far, 22 isoforms have been 
described resulting from alternative splicing [62, 63]; however, only the full-length isoform, 
which retains the reverse transcriptase activity, is able to elongate telomeres [64, 65]. Variants 
that lack the reverse transcriptase domain could affect telomerase activity by acting as com-
petitive inhibitors as reported for the α-variant [66] or may have by themselves telomere- 
independent activities [62, 67, 68]. However, these experiments should be interpreted cautiously 
because they are based on overexpression conditions that are far beyond the physiological 
conditions.
Telomerase activity is generally well correlated with hTERT expression indicating that hTERT 
is a key regulator of this enzyme. hTERT gene is mostly regulated at the transcriptional level. 
This regulation is complex and includes multiple levels [69, 70].
The hTERT promoter does not have typical transcription-regulatory elements as TATA or 
CAAT boxes but is GC-rich. The core promoter harbors at least five GC boxes and two E-boxes 
(enhancer boxes with the canonical sequence of 5′-CACGTG-3′), which are sites for Sp1 
(specificity protein 1), and c-Myc-binding, respectively, as well as multiple other transcrip-
tion factor-binding sites involved in hTERT gene transcription: E-26 (ETS) family members, 
E2F, AP1 (activator protein 1), p53, p21, HIF (hypoxia-inducible factor), NF-kB, β-catenin, 
CTCF (CCCTC-binding factor), WT1 (Wilms’ tumor 1), and MZF2 (myeloid zinc finger 2) [71] 
(Figure 2).
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2.3.2. Transcriptional regulators of hTERT
The factors that bind hTERT promoter were characterized as transcriptional activators or 
transcriptional repressors or can play both roles depending on the cell type and the cellular 
context. Different factors can sometimes compete for binding to the same site or cooperate 
for binding to adjacent sites on hTERT promoter. Most of the studies concern the effect of 
transcription factors interacting with the core region of hTERT promoter, spanning from −180 bp 
(base pair) upstream to +1 bp downstream of the transcription start site. However, transcrip-
tion factors interacting with a more distant region can also play an important role. Their 
action can be modulated by epigenetic modifications (see below). Therefore, the transcrip-
tional level of hTERT results from a complex regulatory network of all these factors. These 
latter observations can explain the contradictory results that are reported in the literature. 
Given the complexity of hTERT regulation, it is difficult to integrate all the information. In 
addition, many factors indirectly regulate hTERT transcription through their interaction with 
other signaling pathways. All these processes ensure a tight and coordinated control of the 
hTERT gene in order to silence it in most human somatic adult cells. This control is lost in 
most malignant cells.
Recent articles have already reviewed exhaustively the roles of specific regulatory factors of 
hTERT [33, 71, 72]. Here, we have selected the most important ones, those whose binding has 
been demonstrated by in vivo assays, and also those that could be involved in the physiopa-
thology of neuroblastomas.
2.3.2.1. c-Myc/Max/Mad-1
c-Myc and its dimerization partner Max (Myc-associated factor X) bind to regulatory ele-
ments called E-boxes and recruits histone acetyltransferases in order to activate the transcrip-
tion of various genes, including hTERT [73]. c-Myc binds to two canonical E-box sequences 
MZF2 MZF2 MZF2 WT1 Ebox
(myc/mad-1)
Sp1Sp1 CTCF
-600 -500 -400 -200-300 -100 +1TSS +100
Ebox
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Figure 2. Schematic representation of the hTERT promoter: binding sites for various transcription factors are shown. The 
transcription start site (TSS, +1) and the translation start site (ATG, +78) are indicated. Stars indicate hotspot promoter 
mutations. The rs2853669 polymorphism (SNP) is shown in the ETS2-binding site. CTCF: CTCF factor-binding site; 
E-Box: Myc/Mad-family factor-binding site; Sp1: binding site for the SP1 transcription factor; ETS: ETS-domain site; WT1: 
binding site for the Wilms’ tumor 1 transcription factor; MZF2: binding site for the myeloid zinc finger 2 transcription 
factor. Vertical tick marks with dark circles indicate the location of CpG dinucleotides. G4 indicates the localization of 
the G-quadruplex structure that can be adopted by hTERT promoter.
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(5′-CACGTC-3′) found in the core promoter of hTERT (at −165 and +44 bp from the tran-
scription start site). This binding leads to the upregulation of hTERT gene, and the increase 
in telomerase activity [74, 75]. However, c-Myc alone is not always sufficient to upregulate 
the expression of hTERT suggesting the requirement of additional factors. For example, the 
cooperation between Sp1 and c-Myc has been demonstrated to upregulate hTERT expression 
in human foreskin keratinocytes transduced by E6 [76]. Recently, it has been reported that 
c-Myc can exert a dual role on hTERT promoter. Indeed, besides its action as a transcriptional 
activator of hTERT, c-Myc can also maintain its promoter in a repressive state [77]. This latter 
action is independent of the two E-boxes.
Numerous factors thereby are able to indirectly upregulate hTERT expression through their 
action on c-Myc expression: transforming growth factor (TGF)-β/Smad signaling, estrogen, 
Aurora-A, Survivin, Leptin, mitogen-activated protein kinase (MAPK)/PI3K (phosphoinosi-
tol-3-kinase)-signaling pathway, MMP9, and Sirtuin 1 (SIRT1). Conversely, many factors are 
able to repress hTERT expression by counteracting the c-Myc expression or activity. The most 
important one is Mad-1 (Max dimerization protein 1), a potent antagonist of c-Myc, which 
acts as a direct competitor for dimerization with Max and binding on the E-boxes. Other fac-
tors are also known to act on c-Myc expression and/or inhibit its binding to hTERT promoter: 
breast cancer 1 (BRCA1), p27KIP21, HIF-1alpha, and so on.
Despite the strong evidence of the action of c-Myc as a transcriptional activator of hTERT, 
several studies reported the lack of correlation between c-Myc expression and hTERT mRNA 
levels [78, 79]. However, in these studies, the direct binding of c-Myc on hTERT promoter has 
not been investigated.
NBL cells generally do not express c-Myc but N-MYC, a protein belonging to the same family. 
c-Myc and N-MYC are encoded by different genes but have similar structures and domains. 
As c-Myc, N-MYC protein was shown to be recruited to the hTERT promoter and to activate it 
in NBL [80]. However, it is not known whether N-MYC can always functionally replace c-Myc 
in hTERT regulation. Moreover, hTERT has been shown to regulate c-Myc protein stability by 
interacting directly with c-Myc suggesting the existence of a feed-forward loop. In addition, in 
c-Myc-driven lymphoma, hTERT can also be recruited to c-Myc target promoters [81]. Such a 
crosstalk between hTERT and N-MYC protein has not been reported in NBL yet.
2.3.2.2. Specificity protein 1 (Sp1)
Sp1 is a transcription factor that binds to GC-box motifs in the promoter of hTERT. It activates 
hTERT gene expression in telomerase-positive cells but suppresses it in telomerase-negative 
one [82]. Sp1 may work in cooperation with c-Myc to upregulate hTERT expression. However, 
in cooperation with Sp3, another GC-box binding protein, Sp1 can also suppress the expres-
sion of hTERT.
It is important to note that this GC-rich region of hTERT promoter is able to form a tandem 
G-quadruplex structure [83]. The formation and stabilization of these structures that involves 
at least three of the five Sp1-binding sites could, therefore, interfere with hTERT transcrip-
tional regulation.
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2.3.2.3. Nuclear factor κ-light-chain-enhancer of activated B cells (NF-kB)
NF-kB is a transcription factor complex playing a role in telomerase expression and activity 
either directly through its binding on hTERT promoter or indirectly through the modula-
tion of the expression of transcription factors known to affect hTERT expression. The bind-
ing site of NF-kB on hTERT promoter is located 600 bp upstream of the ATG translation start 
codon. However, recently, another pathway for the activation of hTERT by this complex 
has been proposed. This new mechanism involves a hotspot hTERT promoter mutation (see 
below).
2.3.2.4. Upstream stimulatory factor (USF) proteins
As c-Myc, USF proteins bind directly to E-box motifs on the core promoter of hTERT. They 
play both activating and repressing roles in the regulation of hTERT gene expression depend-
ing on the cell context.
2.3.2.5. CCCTC-binding factor
CTCF transcription factor binds at the beginning of exon 1 (+4 to +39 bp) and near the begin-
ning of exon 2 (+422 to +440 bp) relative to the ATG in hTERT promoter. It is a repressor of 
hTERT transcription. CTCF is unable to bind to methylated DNA and therefore its binding is 
dependent on the degree of DNA methylation [84].
2.3.2.6. Wilms, tumor protein 1
WT1 is described as a repressor of hTERT. Its binding site lies from −358 to −349 bp on hTERT 
promoter [85]. However, similar to CTCF, the binding of WT1 is known to be methylation-
sensitive. This observation was further supported by Azouz et al. whose experiments, in an 
acute promyelocytic leukemia (APL) cell model, showed that hypermethylation of a distal 
domain of hTERT promoter induced by retinoic treatment prevented WT1 binding and there-
fore, the subsequent hTERT gene repression [86]. A recent study reports an inverse correla-
tion between WT1 expression and MYCN amplification and expression. Moreover, a high 
expression of WT1 has been associated with a poor outcome only for patients showing non-
MYCN-amplified tumors [87]. In a cohort of 67 primary NBL tumors, no significant correla-
tion between WT1 and hTERT expression was found (p = 0.056), whereas, considering only 
stage 4 tumors (n = 51), there was a significant higher WT1 expression in patients with a low 
hTERT expression (p = 0.033).1
2.3.3. hTERT promoter mutations
Recently, hotspot promoter recurrent mutations were identified first in sporadic and familiar 
malignant melanoma [88, 89]. These mutations, which cause an adenine-to-cytosine (A>C) 
mutation or a cytosine-to-thymine (C>T) transition at chromosome 5: 1,295,161, 1,295,228, and 
1 E. Ségal-Bendirdjian et al., unpublished results.
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1,295,250 (−57, −124, and −146 bp upstream of the ATG translation start codon), are named 
−57A>C (or A161C), −124C>T (or C228T), and −146C>T (or C250T), respectively. From there, 
the hTERT promoter mutations have been identified in various types of cancers with different 
frequencies [90]. The two main mutations, −124C>T and −146 C>T, have been suggested to be 
oncogenic drivers on the basis of experimental data showing that (1) their introduction into 
the hTERT promoter reporter could significantly enhance the promoter activity [91]; (2) the 
creation of these mutations by genome editing in hTERT promoter of human pluripotent stem 
cells is sufficient to inhibit the repression of hTERT gene transcription normally observed 
in wild-type hTERT promoter-bearing stem cells after induction of differentiation [92]; and 
(3) tumors carrying hTERT promoter mutations were frequently observed to express higher 
levels of hTERT mRNA and telomerase activity compared with those carrying a wild-type 
promoter. The frequency of the −124C>T mutation is generally higher than the frequency 
of the −146C>T mutations (80 vs. 20%). Other less common mutations were also detected in 
the hTERT promoter such as the CC>TT mutations at −124/−125 (Chr.5: 1,295,228–1,295,229) 
and −138/−139 (Chr.5: 1,295,242–1,295,243) positions. Note that these mutations occur in the 
G-rich region of the promoter known to form G-quadruplex structures [83]; therefore they 
can abrogate their negative effect on transcription by changing their stability and/or altering 
their recognition.
hTERT promoter mutation rates vary significantly from undetectable to 85% among studied 
human cancer types. The mutations occur most frequently in bladder, thyroid, hepatocellu-
lar cancers, malignant glioblastoma, and melanoma [93–96], while they are rarely present in 
hematological malignancies, prostate, gastrointestinal, breast, and lung cancers [90, 97, 98]. 
That a high frequency of hTERT promoter mutations was found in a multitude of advanced 
cancers suggests their key role in the reactivation of telomerase activity.
Mechanistically, −124C>T or −146C>T mutation generates an 11-base nucleotide stretch 
(5′-CCCCTTCCGGGG-3′), which contains a consensus-binding site (GGAA in reverse comple-
ment) for ETS family transcription factors [99]. It was shown that the multimeric GA-binding 
protein (GABP), an ETS family transcription factor, was specifically recruited to the mutant 
rather than wild-type hTERT promoter in different cancer cells. This recruitment is associ-
ated with an enhanced enrichment of active chromatin leading to the opening of chromatin, 
an increased recruitment of PolII, and upregulation of hTERT expression and activity [91, 
100]. This effect is further enhanced by the activation of the non-canonical NF-kB-signaling 
pathway. Indeed, the recruitment of the p52 subunit of NF-kB to the C250T site facilitates the 
stimulation of hTERT transcription.
Genome-wide association studies revealed the presence of single-nucleotide polymorphisms 
(SNPs) within the hTERT locus that were associated with increased risks in a variety of can-
cers. For example, rs2736100, located in intron 2, was associated with various types of cancer 
as glioma and colorectal cancer [101, 102]. Another SNP, rs2853669, found at hTERT promoter 
upstream of the first E-box, disrupts an ETS2-binding site [103, 104] and also hampers c-Myc 
binding to the adjacent E-box. The presence of this SNP can modify the effects of hTERT pro-
moter mutations [105].
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While hTERT promoter mutations have been identified in a broad range of cancers, not all 
cancers possess these mutations suggesting that other mechanisms contribute to hTERT 
reactivation.
2.3.4. Epigenetic regulation of hTERT transcription
The hTERT promoter is located in a 4-kb CpG island from −1800 to +2200 bp (relative to the 
TSS). Besides the involvement of transcription factors, epigenetic control and overall chroma-
tin structure at hTERT promoter add another layer of hTERT regulation. It is well established 
that DNA methylation, histone acetylation, and methylation are also involved in the regula-
tion of hTERT transcription even though the precise role and the molecular mechanisms are 
not well understood and even contradictory due to the different cellular models studied and 
the various methods used to analyze these epigenetic modifications.
Considering the methylation pattern categorized in different cell lines, it is possible to narrow 
the promoter to only two regions: one methylated, sometimes hypermethylated (from −650 
to −200 bp from ATG) and one unmethylated or only slightly methylated (from −200 to +100 bp) 
[86, 106–110].
It is known that DNA methylation at gene promoter plays a major role in transcription factor 
binding. For example, hypomethylation at the hTERT core promoter may allow the binding of 
c-Myc to the E-boxes. Some reports, including ours, suggest that DNA methylation of hTERT 
promoter might have a key role in hTERT expression, but in a way opposite to what has been 
proposed so far. The hypothesis is that DNA methylation at hTERT promoter can contribute 
to prevent the binding of repressors and could account for high hTERT expression. This has 
been demonstrated for two transcription factors known to repress hTERT: CTCF whose bind-
ing site is located in exon 1 [71, 111, 112] and WT1 whose binding site is located in the distal 
promoter [86].
Besides DNA methylation, histones contribute to chromatin organization. Modifications can 
occur to their amino acid tails: methylation and acetylation are the most common. In general, 
methylation of histone 3 at its lysine 4 (H3K4) and hyperacetylation of histones are signs of 
hypo- or unmethylated DNA and active transcription gene. On the contrary, methylation of 
lysine 9 and 27 of histone 3 (H3K9 and H3K27, respectively) and hypoacetylation of histones 
are signs of hypermethylated DNA, so inactive transcription gene [110].
2.4. Human TR regulation
As hTERT is generally expressed only in telomerase-positive cells and its ectopic introduction 
alone can immortalize normal human cells, hTERT has been regarded as the limiting compo-
nent of telomerase activity and much of the research has thus focused on the regulation of 
hTERT gene. However, even though hTR is ubiquitously expressed, evidence supports the 
notion that hTR can be also limiting for telomerase activity and telomere maintenance [113]. 
Indeed, the gene encoding hTR, a single-copy gene located on chromosome 3 at 3q26.3 [114], 
is highly regulated. A number of transcription-binding sites have been validated by either 
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electrophoretic mobility gel gift assays, promoter reporters, and chromatin immunoprecipi-
tation (ChIP) experiments, including Sp1, Sp3, and NF-Y [115, 116]. Furthermore, different 
signaling pathways have also been implicated in hTR transcription as JNK pathway.
3. Telomeres and telomerase in neuroblastoma
3.1. Telomerase as a biological marker and predictive factor in neuroblastoma
Several distinguishable groups in NBL have been identified based on their telomere biology 
and telomerase activation suggesting that telomerase expression may be one critical step in the 
development of neuroblastoma [5]. High telomerase activity allowing the maintenance of telo-
mere length has been previously reported to correlate with advanced stages of the disease and 
with poor prognosis [5, 117–121]. By contrast, tumors without detectable telomerase activity 
showed favorable outcomes and some tumors regressed or matured [122]. This phenomenon 
of spontaneous regression led to propose a specific pattern of the metastatic disease called 
stage 4S. Children with stage 4S were restricted to infants aged less than 12 months at diag-
nosis, had generally small primary tumors with dissemination limited to the liver and skin 
and minimum bone marrow involvement [123]. The mechanisms involved in this regression 
remain to be elucidated. The expression of the alternate splice variants of hTERT could consti-
tute a negative regulatory mechanism of telomerase at the posttranscriptional level and might 
account for the favorable evolution of these tumors [119, 124]. Therefore, full-length hTERT 
expression and telomerase activity, due to its strong correlation with the biological behavior 
of neuroblastoma tumors, may prove to be a good indicator of malignancy, in particular in 4S 
neuroblastoma. This may have consequences in the therapeutic strategies that can be adopted 
for these patients. As this form presents similar features as classic stage 4, it can be therefore 
treated as a high-risk group although in these cases, less therapeutic intensity could be given.
Several mechanisms have been proposed to explain the phenomenon of spontaneous regres-
sion. These include the neurotrophin receptor signaling when deprivation in nerve growth factor 
occurs, immune-mediated killing by anti-neural antibodies in patients, epigenetic regulation of 
gene expression through DNA methylation, histone modifications or chromatin remodeling, and 
finally telomere shortening and consequently apoptosis. Indeed, most of the tumor samples from 
4S NBL have low telomerase activity or short telomeres [5]. This mechanism is further supported 
by Samy et al. who showed that a neuroblastoma cell line transfected by a dominant-negative 
form of human telomerase was more prone to apoptosis and had reduced tumorigenicity in a 
mouse xenograft model compared to untransfected neuroblastoma cells [125].
A correlation between hTR expression in primary NBLs, stage of disease, and survival [126, 
127] has also been reported demonstrating a potential role for hTR as a biomarker even though 
most of the studies focused on hTERT expression. However, hTR expression does not always 
correlate with telomerase activity. This can be explained by the complexity of the different 
molecular mechanisms involved in telomerase regulation.
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Even though the main role of telomerase is to maintain telomere length in tumors, non-canonical 
functions could also promote tumor growth and contribute to poor prognosis in primary 
NBLs (Wnt signaling, DNA repair, genomic instability, apoptosis, and escape from oncogene-
induced senescence) [117].
Using a novel approach of three-dimensional (3D) telomere quantitative fluorescence in situ 
hybridization on 74 NBL tissue samples, a recent report demonstrates a possible classification 
of NBLs based on the level of telomere dysfunction, telomere length, and nuclear organiza-
tion. Telomere dysfunctions were associated with unfavorable tumor characteristics, includ-
ing MYCN amplification, and poor prognosis [128].
3.2. Potential mechanisms of hTERT activation and/or telomere maintenance 
mechanisms in neuroblastoma
The mechanisms by which telomerase activity is activated in high-stage NBL remain elusive. 
However, recent studies have shed some light on this important question. Although some 
controversies may remain, hTERT expression upregulation may occur through at least two 
pathways: MYCN amplification and genomic rearrangements around hTERT. Alternatively, 
ALT pathway can be activated in the absence of telomerase activation providing a mean for 
tumor cells to stabilize their telomeres as a necessary requirement for the immortalization and 
progression of the tumors.
3.2.1. MYCN amplification
MYCN amplification is the best characterized genetic marker and a powerful prognostic indi-
cator of high-risk neuroblastoma [3]. MYCN-amplified tumors usually exhibit high telomer-
ase activity and expression [118]. As developed earlier, c-Myc-binding sites are present on 
hTERT gene promoter and it is now well demonstrated that this factor, alone, or in coopera-
tion with other transcription factors, determines the activity of hTERT promoter. N-MYC and 
c-Myc proteins are highly homologous. As c-Myc, N-MYC heterodimerizes with Max at con-
sensus E-box sequences, therefore, MYCN overexpression could promote telomere stabiliza-
tion through a transcriptional increase of hTERT gene expression associated with an increase 
in telomerase activity even though only one study reported such a direct interaction by ChIP 
in NBL [80]. An inverse correlation of MYCN and c-Myc expression was found in NBL sub-
types [129]. As mentioned earlier, whether N-MYC protein can replace all c-Myc functions for 
hTERT regulation is still an unanswered question. Several lines of evidence suggest that MYC 
family members have separate physiological functions. The interplay between N-MYC and 
hTERT in NBL needs, thus, to be further investigated.
A recent study shows that DKC1 gene promoter is targeted by both c-Myc and N-MYC and 
that high DKC1 expression is an independent prognostic indicator for adverse clinical out-
come in NBL. DKC1 gene encodes the RNA-binding protein dyskerin, a core component of 
the telomerase holoenzyme. This new function of DKC1 in NBL appears to be telomerase-
independent [130].
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3.2.2. hTERT promoter mutations
Although hotspot mutations in hTERT promoter driving telomerase activity are frequently 
described in neural crest-derived tumors such as melanoma [88, 89] and in a variety of other 
neuronal tumors including medulloblastoma and glioma [90, 131, 132], no hTERT promoter 
mutations have been detected in a large series (n = 131) of primary neuroblastoma [133], in 
line with previous studies performed on a smaller number of patients [90, 134]. However, 
these mutations were searched only in the core promoter of hTERT; it is not excluded that 
mutations may exist in more distant regulatory elements. The existence of a given SNP should 
also be searched.
3.2.3. hTERT gains
Chromosome 5p is often amplified in NBL, and focal hTERT gains were recently detected in 
several stage 4 primary NBLs. hTERT gains were more frequently detected in MYCN non-
amplified cases, suggesting that hTERT gain performs a function similar to MYCN amplifi-
cation [135, 136]. As N-MYC protein can bind and activate hTERT promoter, it is likely that 
hTERT gains are selected in order to increase hTERT expression in the absence of MYCN 
amplification.
3.2.4. hTERT rearrangements
Recent whole-genome sequencing of primary neuroblastoma, performed by two independent 
groups, discovered recurrent genomic rearrangements in a 70-kb region proximal to hTERT 
locus on the chromosome 5p15.33 [9, 10].
Indeed, in the first study [10], the authors were searching for structural alterations that might 
occur in high-risk NBL and, analyzing 56 tumors, they identified 4 locations exhibiting clus-
tered breakpoints. These are related to MYCN amplifications, ATRX deletions, copy num-
ber gains of chromosome 17q, and rearrangements located at chromosome 5p15.33 proximal 
to hTERT gene. hTERT rearrangements occurred in 21% of tumors and included balanced 
translocations, copy number gains, high-level amplifications, and chromothripsis [137]. 
Chromothripsis corresponds to a massive and localized genome rearrangement [138], affect-
ing high-risk tumors. Chromothripsis occurs in 2–3% of human cancers and, in a whole- 
genome-sequencing study, it occurs in 18% of high-risk NBL [137]. In an extended case series 
(n = 217), the authors showed that hTERT rearrangements are associated with a poor patient outcome 
and occur in mutually exclusive fashion with MYCN amplification and ATRX mutations (see 
below). They do not affect directly the hTERT gene or its promoter but they are all associ-
ated with an increase in hTERT transcription and telomerase activity as well as genes present 
in its vicinity (SLC6A18 and SLC6A19) [139]. ChIP sequencing of hTERT-rearranged tumors 
indicated next to the breakpoints the presence of histone modifications known to mark active 
promoters (H3K4me3 and H3K27ac) and transcription elongation (H3K36me3), whereas in 
cells lacking hTERT alterations the repressive mark H3K27me3 was identified. Therefore, the 
structural rearrangement occurring at 5p15.33 results in a massive chromatin remodeling of 
this genomic region. The biological effect is the repositioning of regulatory elements very close 
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to hTERT locus that could be responsible for the high induction of hTERT expression (up to 90 
times that of normal cells) in these tumors.
In a similar whole-sequencing study [9] screening 108 NBLs, structural rearrangements of 
hTERT associated with hTERT overexpression were identified in 23% of cases. In hTERT-
rearranged NBLs, a significant increase in telomere length has been demonstrated compared 
to non-rearranged NBLs. Both studies describe hTERT rearrangement as the second most 
frequent genetic defect in high-risk NBL after MYCN alteration. It is important to note that in 
those cases the promoter and coding regions of hTERT gene remain non-altered.
These results have been major advances in our understanding of NBL genetic and biology 
placing telomere biology at the core of this pathology.
3.2.5. Small nucleolar ribonucleoproteins (snoRNPs)
A recent study reported that the expression of proteins involved in the formation and sta-
bilization of snoRNP complex (including DKC1, GAR1, and NHP2 proteins) is elevated in 
high-risk NBL and associated with poor prognosis. Furthermore, this study shows a posi-
tive correlation between DKC1 expression and telomerase activity. This increase is associated 
with an increase of hTR expression. Therefore, in NBL, upregulation of snoRNPs may contrib-
ute to telomere maintenance and stabilization [140].
3.2.6. ALT and neuroblastoma: ATRX (alpha thalassemia/mental retardation syndrome, X-linked) 
mutations
Telomere length does not necessarily correlate with telomerase activity [141]. Recently, it has 
been reported that some neuroblastomas (generally associated with unfavorable NBL in older 
children without MYCN amplification and regardless of telomerase activation status) pre-
serve their telomere length in the absence of telomerase through telomere-binding proteins 
and alternative lengthening of telomeres, a process based on DNA repair/homologous recom-
bination pathways [141–143]. ALT tumors represent 10–20% of NBL. These tumors have a 
very poor outcome. Phenotypically, ALT cells present long and heterogeneous telomere 
lengths [144], ALT-associated promyelocytic leukemia (PML) nuclear bodies [145], and abun-
dant extra-chromosomal telomeric repeats [146]. A recent whole-genome-sequencing study 
identifies, in most ALT NBL cases, loss-of-function mutations in ATRX [137, 147, 148]. ATRX 
maps to the X chromosome and encodes a SWI/SNF chromatin-remodeling ATP-dependent 
helicase. ATRX regulates chromatin structure at both centromeric heterochromatin and telo-
meric regions [149]. In vitro analyses demonstrate its binding to GC-rich sequences and to 
G-quadruplexes [150]. Loss of ATRX functions may allow the destabilization of repressive 
heterochromatin at telomeres. NBLs with ATRX mutations show longer telomeres. ATRX 
mutations include in-frame deletions, missense, nonsense, and frameshift single-nucleotide 
variations. They are predominantly observed in adolescent and young adult patients (44% in 
patients older than 12 years, whereas no mutation was detected in infants <18 months of age 
[148]) and are frequently associated with chemo-resistance. ATRX protein establishes a func-
tional interaction with DAXX (death domain-associated protein). At telomeres, ATRX and 
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DAXX proteins cooperate to deposit the histone H3 variants, H3.3, to maintain chromosome 
stability [151]. Loss of function of ATRX/DAXX is also associated with ALT activation [152] 
and poor overall survival among older patients. As mentioned earlier, ATRX mutations were 
mutually exclusive from MYCN amplification. However, how ATRX mutations lead to NBL 
progression is still an unanswered question.
3.2.7. ARID1A and ARID1B
Next-generation sequencing, genome-wide rearrangements analyses, and targeted analysis of 
specific genomic loci of 71 NBL patients identified mutations in chromatin-remodeling com-
plexes encoded by ARID1A/1B (AT-rich interaction domain 1A/1B) genes in 11% of cases with 
decreased survival of patients [147]. Both proteins are subunits of the SWI/SNF transcrip-
tional complex. They have emerged as tumor-suppressor genes and thereby when mutated 
can drive NBL tumorigenesis. However, additional studies will be required to elucidate the 
role of these proteins in the initiation or progression of NBL.
In conclusion, it is important to note that through either MYCN amplification, hTERT rear-
rangements, or ATRX/DAXX mutations, most high-risk NBLs have activated mechanisms, all 
of which are involved in the maintenance of telomere length and contribute to the tumor pro-
gression. This relationship highlights the major role of telomere/telomerase biology in NBL. 
These three mechanisms identify therefore distinct groups of NBL patients at very high risk 
with poor outcome [139]. That low-risk tumors lack such alterations support the notion that 
these kinds of tumors are more prone to spontaneously regress.
Altogether, these observations provide new important mechanisms that could be targeted in 
new therapeutic strategies to treat the most aggressive forms of neuroblastoma.
4. Telomerase, a target for cancer therapeutics
That, on one hand, both MYCN amplification and 5p15.33 rearrangement targeting hTERT 
locus lead to an increase in telomerase activity and subsequent telomere lengthening, and on 
the other hand ALT pathway is activated in tumors lacking hTERT or MYCN alterations indi-
cate that the fate of high-risk NBL is largely dependent on telomerase/telomere biology. These 
new findings may help to improve tumor diagnostics and prognosis but also supports the 
development of novel therapeutic strategies targeting telomere/telomerase to treat the most 
aggressive form of this disease. Different molecules were shown to target telomerase by differ-
ent mechanisms such as nucleoside analogs and reverse transcriptase inhibitors (zidovudine, 
stavudine, and tenofir), synthetic non-nucleoside inhibitors as BIBR1532 (2-[(E)-3 naphtalen-
2-yl-but-2enoylamino]-benzoic acid), natural compounds (EGCG, MST-132), G-quadruplex 
stabilizers (telomestatin, BRACO-19), and molecular chaperone inhibitors affecting hTERT 
assembly (Hsp90 inhibitors). However, these compounds generally lack specificity and have 
adverse effects, and for now, no clinically validated drug targeting telomerase has been suc-
cessfully developed. GRN163L (imetelstat), a phosphoramidate oligonucleotide targeting the 
template region of hTR, has undergone clinical trials by Geron Corporation (Menlo Park, 
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CA, USA) [153–155]. However, the phase II study has been discontinued in breast cancers 
and non-small-cell lung carcinoma because no significant improvement in median progres-
sion-free survival was demonstrated. Moreover, hematological toxicity has been observed. 
However, these side effects have been used to propose this drug in hematological diseases. A 
phase II study evaluating the activity of imetelstat in patients with essential thrombocythemia 
or polycythemia vera is in progress. However, the actual mechanism of action of this molecule 
is still to be determined. For now, no clinical trials have been performed on NBL.
Regarding NBL, perhaps future attempts could be to target specifically N-MYC protein in 
patients who have NBL with MYCN amplification. However, the lack of specificity of the 
strategies targeting directly transcription factors is still a major concern. Bromodomain and 
extra terminal (BET) inhibitors, as JQ1 to specifically downregulate MYCN expression, are 
at the preclinical stage of evaluation [156]. Small molecules have been identified to inhibit 
c-Myc/Max interaction as well as decrease c-Myc protein levels and inhibit cell growth [157]. 
It has been shown that these molecules also interfere with N-MYC/Max interaction resulting 
in cell cycle arrest in MYCN-overexpressing NBL cell lines [158]. The consequences on hTERT 
expression have not been investigated yet.
The recent identification of ATRX mutations associated with their consequences on telomere 
structure in a specific group of high-risk NBL patients suggests that G-quadruplex stabilizers 
could be a potential therapeutic strategy to partially reverse the effects of ATRX mutations.
Telomerase expression was proposed as a selectively targetable mechanism for retinoids and 
specifically all trans retinoic acid (ATRA), an already clinically relevant drug used to stimulate 
differentiation of APL. Indeed, in a APL cellular model, it has been shown that retinoids can 
induce transcriptional repression of hTERT gene not only in differentiation of sensitive cells 
but also in cells resistant to ATRA-induced differentiation [159–161]. As the mechanism of 
hTERT repression occurs at the level of gene transcription, all the functions of telomerase can 
thus be targeted. Therefore, it is worth considering this antitelomerase property of retinoids 
in combination with more conventional therapies to target NBL. A recent study reporting the 
efficacy of a combination therapy, using retinoids and epigenetic modulators, in reducing 
NBL cell growth supports this idea [162].
5. Conclusions
Several potential chemotherapy strategies based on telomerase and telomere biology have 
been developed and explored by pharmaceutical and biotechnology companies [163]. 
However, in spite of ever-growing knowledge on telomere and telomerase biology, a number 
of questions remain to be answered as most of these numerous strategies are not yet clinically 
available because of a weak efficiency and/or a high toxicity. Therefore, to develop agents that 
will be effective, we need a sharper picture of how the enzyme functions and how we can 
manage to target specifically and destabilize telomeres in cancer cells. Epigenetic therapies 
aimed at counteracting the genetic alterations (mutations) are emerging alternatives against 
aggressive tumors.
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Telomerase regulation is highly complex, involving the interplay between numerous biologi-
cal and molecular processes. Despite the extensive studies that have been already done, a 
lot more is necessary to unravel the mechanisms underlying the switching off/on of hTERT 
gene during cell differentiation and cell transformation. However, progress in this direction is 
hampered by the absence of standardized methods to measure hTERT expression and telom-
erase activity and the lack of suitable tools in the study of telomere/telomerase biology.
First, telomerase repeated amplification protocol (TRAP) assay is a rather artificial assay to 
quantify telomerase activity; it is based on a quantitative real-time polymerase chain reac-
tion (PCR) method that measures only the capacity of the telomerase reverse transcriptase to 
elongate artificial telomeric substrates without giving any measurement of the other functions 
of this protein. To date, no assay exists to evaluate the non-conventional functions of hTERT.
Second, hTERT expression is generally quantified using also a quantitative real-time PCR; 
however, in most cases it is not clearly known which hTERT isoform (full-length or specific 
splice variants) is detected. This would explain why, sometimes, comparison between telom-
erase activity and hTERT transcripts yielded contradictory results. Indeed, generally exhaus-
tive measurements using different primer sets for the detection of various hTERT isoforms 
are not usually done. The detection and quantification of splice variants can be of interest for 
clinical outcome and prognosis. Moreover, further studies are also required to define pre-
cisely the functions of these variants.
Third, hTR is rarely quantified; however, it is also a limiting factor in telomere homeostasis.
Finally, due to the low expression of telomerase even in cancer cells, the detection of telom-
erase by western blot or fluorescence is puzzling. In addition, commercially available anti-
hTERT antibodies are still a problem with specificity [164]. Because of these limitations, 
several published studies used overexpressed hTERT protein (generally tagged). However, 
the unusually high concentration of the protein due to the overexpression could alter the 
dynamic and the localization of the protein compared to the endogenous protein leading to 
misinterpretations.
Since the first paper published in 1995 [5], very few scientific advances have been done on a 
potential involvement of telomere/telomerase in NBL biology. However, the recent findings 
highlighting the role of telomere/telomerase biology in high-risk NBL will definitely impact 
the research in this pathology as well as in other cancers and help to develop new therapeutic 
strategies.
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